Company Overview and News

3
AGTC / Applied Genetic Technologies Corp FORM 8-K (Current Report)

2018-07-03 sec.gov
Form 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AGTC

1
AGTC / Applied Genetic Technologies Corp null

2018-07-03 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C4P(# @;V)J#3P\+TQI;[email protected],O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](.)-B7 8E/[email protected]&-&)[email protected] $& #71P?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,B P(&]B:@T\/"]#(#8Y+T9I;'1E
AGTC

40
AGTC / Applied Genetic Technologies Corp S-3/A

2018-06-15 sec.gov
S-3/A Table of Contents As filed with the Securities and Exchange Commission on June 15, 2018 Registration Statement No. 333-225286
AGTC

123
AGTC Announces Expansion of Clinical and Regulatory Leadership Teams

2018-06-14 globenewswire
20+ Year Medical Affairs and Ophthalmology Veteran, Lanita C. Scott, M.D., Appointed as Vice President of Clinical Research and Medical Affairs
AGTC REGN BMYMP BMY

157
MeiraGTx IPO: Hedge Fund Managers Are Leading The Company

2018-06-04 seekingalpha
With brilliant individuals inside MeiraGTx Holdings plc (MGTX), the institutional investors should have a look at the four candidates in Phase 1-2. Sophisticated underwriters, such as Bank of America Corporation (NYSE:BAC), Barclays PLC (NYSE:BCS), Evercore and Chardan, are working with the company.
AGTC BCS BCS.PRD BCS.PRC BCS.PRA ONCE BAC GS 83SF NITE BCS.PR 83SK 47MC

41
AGTC / Applied Genetic Technologies Corp S-3

2018-05-30 sec.gov
S-3 Table of Contents As filed with the Securities and Exchange Commission on May 30, 2018 Registration Statement No. 333-
AGTC

39
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q3 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Applied Genetic Technologies Corporation (NASDAQ:AGTC) Q3 2018 Earnings Conference Call May 8, 2018 4:30 PM ET
AGTC

39
40
123
Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors

2018-04-18 globenewswire
WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of Susan Washer to its Board of Directors.
ABT AGTC HSGX ABT

39
AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

2018-04-18 globenewswire
GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has dosed the first patient in the Company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP).
AGTC

40
AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)

2018-04-10 globenewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the completion of enrollment in a clinical study of the company's gene therapy product candidate, in collaboration with Biogen, for the treatment of x-linked retinoschisis (XLRS).
AGTC

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

CUSIP: 03820J100